Bristol Myers Squibb stock holds on to earnings metrics and pipeline scale

Bristol Myers Squibb (US0897961004) is framed today by its latest reported revenue, profit, and capital-return numbers rather than a fresh market catalyst. The company reported $46.2 billion in revenue for fiscal 2025, $8.0 billion in net income for fiscal 2025, and $7.4 billion in adjusted EPS for fiscal 2025, giving investors a current operating baseline.

Fiscal 2025 revenue at $46.2 billion

The $46.2 billion fiscal 2025 revenue figure matters because it sets the scale of the business after a year that also included $8.0 billion in net income and $7.4 billion in adjusted EPS. Those figures are the most recent full-year anchors available in the company’s investor materials and define the backdrop for any read-through on valuation and execution.

Capital return is part of that same picture. Bristol Myers Squibb paid a quarterly dividend of $0.62 per share, equal to $2.48 on an annualized basis, while maintaining a large commercial footprint across oncology, hematology, immunology, and cardiovascular therapy.

Profit and EPS base

Profitability still reads as a central watchpoint for Bristol Myers Squibb stock. The company’s fiscal 2025 net income of $8.0 billion and adjusted EPS of $7.4 both provide a concrete reference point for comparing future quarters against the most recent full-year result.

The same baseline also helps frame balance-sheet and cash-return questions. For long-only shareholders, the combination of a $46.2 billion revenue base and a $2.48 annualized dividend is more informative than a headline-level move alone because it ties current operating scale to shareholder yield.

Revenue, EPS, and yield

Relative comparisons are straightforward from those full-year figures. Revenue of $46.2 billion and adjusted EPS of $7.4 in fiscal 2025 are the clearest dated numbers in the current public set, and the annualized dividend of $2.48 adds a third quantified reference point.

That mix points to a company where execution on margins, pipeline conversion, and patent-cycle management remains as important as top-line growth. The investor lens is therefore not just on sales, but on how much of those sales translate into durable earnings and cash distribution.

Opdivo and other medicines

Opdivo remains one of Bristol Myers Squibb’s most visible products, and the company’s oncology franchise still shapes how the market reads the group. The product mix is important because large companies in this category often depend on a limited number of major medicines to carry a significant share of revenue and profit.

That is why the reported fiscal 2025 numbers matter beyond the headline. A $46.2 billion revenue base, $8.0 billion in net income, and $7.4 billion in adjusted EPS imply a business that is still large enough to absorb R&D, launch costs, and portfolio shifts without losing scale overnight.

Closing price context

Bristol Myers Squibb stock is discussed here without a live quoted price because the current body of evidence is centered on fiscal 2025 operating results and shareholder returns. For investors, the most concrete context remains the company’s $46.2 billion revenue base, $8.0 billion net income, and $2.48 annualized dividend, all tied to fiscal 2025.

On that basis, Bristol Myers Squibb remains a large-cap pharmaceutical name whose valuation conversation is still anchored by earnings power and product concentration rather than by a single day’s move.